From the Department of Molecular Biotechnology and Health Science, University of Torino, Via Nizza 52, 10126 Turin, Italy (E.G., P.B., F.A., R.S., E.D.G., R.I., S.A.); and Centro di Eccellenza di Imaging Preclinico (CEIP), Colleretto Giacosa, Italy (P.B., F.A., S.A.).
Radiology. 2017 Dec;285(3):839-849. doi: 10.1148/radiol.2017162857. Epub 2017 Sep 4.
Purpose To evaluate the speciation of gadolinium-containing species after multiple administrations of the gadolinium-based contrast agents (GBCAs) gadodiamide and gadoteridol and to quantify the amount of intact gadolinium complexes and insoluble gadolinium-containing species. Materials and Methods A total dose of 13.2 mmol per kilogram of body weight of each GBCA was administered in healthy Wistar rats over a period of 8 weeks. Three days after the final administration, rats were sacrificed, and the brains were excised and divided into three portions. Each portion of brain homogenate was divided into two parts, one for determination of the total gadolinium concentration with inductively coupled plasma mass spectrometry and one for determination of the amount of intact GBCA and gadolinium-containing insoluble species. Relaxometric measurements of gadodiamide and gadolinium trichloride in the presence of polysialic acid were also performed. Results The mean total gadolinium concentrations for gadodiamide and gadoteridol, respectively, were 0.317 μg/g ± 0.060 (standard deviation) and 0.048 μg/g ± 0.004 in the cortex, 0.418 μg/g ± 0.078 and 0.051 μg/g ± 0.009 in the subcortical brain, and 0.781 μg/g ± 0.079 and 0.061 μg/g ± 0.012 in the cerebellum. Gadoteridol comprised 100% of the gadolinium species found in rats treated with gadoteridol. In rats treated with gadodiamide, the largest part of gadolinium retained in brain tissue was insoluble species. In the cerebellum, the amount of intact gadodiamide accounts for 18.2% ± 10.6 of the total gadolinium found therein. The mass balance found for gadolinium implies the occurrence of other soluble gadolinium-containing species (approximately 30%). The relaxivity of the gadolinium polysialic acid species formed in vitro was 97.8 mM/sec at 1.5 T and 298 K. Conclusion Gadoteridol was far less retained, and the entire detected gadolinium was intact soluble GBCA, while gadodiamide yielded both soluble and insoluble gadolinium-containing species, with insoluble species dominating. RSNA, 2017 Online supplemental material is available for this article.
评估多次使用基于钆的造影剂(GBCA)钆喷酸葡胺和钆特醇后含钆物种的形态,并定量测定完整的钆络合物和不溶性含钆物种的量。
在 8 周的时间内,每公斤体重给予 13.2 毫摩尔的每种 GBCA 总量。最后一次给药后 3 天,处死大鼠,取出大脑并分为 3 部分。每个脑匀浆部分分为两部分,一部分用于通过电感耦合等离子体质谱法测定总钆浓度,另一部分用于测定完整的 GBCA 和不溶性含钆物种的量。还对多涎酸存在下的钆喷酸葡胺和三氯化钆的弛豫度进行了测量。
钆喷酸葡胺和钆特醇的平均总钆浓度分别为 0.317μg/g±0.060(标准差)和 0.048μg/g±0.004,在皮质中,0.418μg/g±0.078 和 0.051μg/g±0.009 在皮质下脑,0.781μg/g±0.079 和 0.061μg/g±0.012 在小脑。在接受钆特醇治疗的大鼠中,发现的所有钆物种中 100%为钆特醇。在接受钆喷酸葡胺治疗的大鼠中,保留在脑组织中的最大部分为不溶性物质。在小脑,完整的钆喷酸葡胺占总发现的钆的 18.2%±10.6。发现的钆的质量平衡表明存在其他可溶性含钆物种(约 30%)。体外形成的钆多涎酸物种的弛豫率在 1.5 T 和 298 K 时为 97.8mM/sec。
钆特醇的保留率低得多,所有检测到的钆都是完整的可溶性 GBCA,而钆喷酸葡胺则产生了可溶性和不溶性的含钆物种,不溶性物种占主导地位。RSNA,2017 在线补充材料可为本文提供。